Cost-Effectiveness of Sunitinib in Patients with Advanced or Metastatic Pancreatic Neuroendocrine Tumors in Portugal
Introduction: Sunitinib is an oral multitargeted tyrosine kinase inhibitor approved in Europe in 2010 for use in well-differentiated pancreatic neuroendocrine tumors (pNET) that have spread or cannot be removed by surgery.
Aim(s): This study evaluated the cost-effectiveness of Sunitinib + best supportive/palliative care (BSC) compared to placebo + BSC in Portuguese patients.
Materials and methods: A Markov model was adapted to predict life-years (LY) and associated costs of pNET patients’ treatment over lifetime. The model tracks transitions of patients between three health states: progression-free, post-progression and death. BSC overall survival (OS) probabilities were adjusted for crossover with a rank preserving structural failure time (RPSFT) statistical analysis. A National Health Service perspective was adopted, costs and effectiveness discounted at 5%.
Conference: 9th Annual ENETSConcerence (2012)
To read the full abstract, please log into your ENETS Member account.